- Home
- MYO vs FULC Comparison
MYO vs FULC Comparison
Compare MYO & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- FULC
- Stock Information
- Founded
- MYO 2004
- FULC 2015
- Country
- MYO United States
- FULC United States
- Employees
- MYO N/A
- FULC N/A
- Industry
- MYO Industrial Specialties
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- MYO Health Care
- FULC Health Care
- Exchange
- MYO Nasdaq
- FULC Nasdaq
- Market Cap
- MYO 178.4M
- FULC 210.9M
- IPO Year
- MYO 2017
- FULC 2019
- Fundamental
- Price
- MYO $4.87
- FULC $3.01
- Analyst Decision
- MYO Strong Buy
- FULC Hold
- Analyst Count
- MYO 4
- FULC 8
- Target Price
- MYO $9.75
- FULC $6.57
- AVG Volume (30 Days)
- MYO 637.2K
- FULC 465.5K
- Earning Date
- MYO 03-10-2025
- FULC 05-12-2025
- Dividend Yield
- MYO N/A
- FULC N/A
- EPS Growth
- MYO N/A
- FULC N/A
- EPS
- MYO N/A
- FULC N/A
- Revenue
- MYO $32,551,198.00
- FULC $80,000,000.00
- Revenue This Year
- MYO $32.15
- FULC N/A
- Revenue Next Year
- MYO $17.59
- FULC N/A
- P/E Ratio
- MYO N/A
- FULC N/A
- Revenue Growth
- MYO 69.17
- FULC 2752.05
- 52 Week Low
- MYO $2.51
- FULC $2.78
- 52 Week High
- MYO $7.17
- FULC $10.13
- Technical
- Relative Strength Index (RSI)
- MYO 42.42
- FULC 40.55
- Support Level
- MYO $5.28
- FULC $3.00
- Resistance Level
- MYO $5.62
- FULC $3.35
- Average True Range (ATR)
- MYO 0.33
- FULC 0.19
- MACD
- MYO 0.00
- FULC 0.03
- Stochastic Oscillator
- MYO 2.72
- FULC 40.71
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.